These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18757400)

  • 41. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.
    Ren SY; Bolton E; Mohi MG; Morrione A; Neel BG; Skorski T
    Mol Cell Biol; 2005 Sep; 25(18):8001-8. PubMed ID: 16135792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
    Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak MZ; Wen SC; Zon G; Gewirtz AM; Perussia B; Calabretta B
    Blood; 1995 Jul; 86(2):726-36. PubMed ID: 7606002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
    Million RP; Aster J; Gilliland DG; Van Etten RA
    Blood; 2002 Jun; 99(12):4568-77. PubMed ID: 12036890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
    Spencer A; Granter N
    Exp Hematol; 1999 Sep; 27(9):1397-401. PubMed ID: 10480430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of Bcr-Abl protein tyrosine kinase on maturation and proliferation of primitive haematopoietic cells.
    Buckle AM; Mottram R; Pierce A; Lucas GS; Russell N; Miyan JA; Whetton AD
    Mol Med; 2000 Oct; 6(10):892-902. PubMed ID: 11126203
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.
    Saussele S; Weisser A; Müller MC; Emgi M; La Rosée P; Paschka P; Kuhn C; Willer A; Hehlmann R; Hochhaus A
    Leukemia; 2000 Nov; 14(11):2006-10. PubMed ID: 11069038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.
    Thomas EK; Cancelas JA; Chae HD; Cox AD; Keller PJ; Perrotti D; Neviani P; Druker BJ; Setchell KD; Zheng Y; Harris CE; Williams DA
    Cancer Cell; 2007 Nov; 12(5):467-78. PubMed ID: 17996650
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
    Czechowska A; Poplawski T; Drzewoski J; Blasiak J
    Chem Biol Interact; 2005 Apr; 152(2-3):139-50. PubMed ID: 15840387
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
    Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
    Griswold IJ; MacPartlin M; Bumm T; Goss VL; O'Hare T; Lee KA; Corbin AS; Stoffregen EP; Smith C; Johnson K; Moseson EM; Wood LJ; Polakiewicz RD; Druker BJ; Deininger MW
    Mol Cell Biol; 2006 Aug; 26(16):6082-93. PubMed ID: 16880519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
    Nakata Y
    Hiroshima J Med Sci; 1993 Jun; 42(2):67-71. PubMed ID: 8253600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Detection of BCR/ABL fusion gene by fluorescence in situ hybridization and its clinical application].
    Zhou RL; Mo YX; Lan M; Lin JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1283-8. PubMed ID: 22040989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders.
    Pastore C; Nomdedeu J; Volpe G; Guerrasio A; Cambrin GR; Parvis G; Pautasso M; Daglio C; Mazza U; Saglio G
    Genes Chromosomes Cancer; 1995 Oct; 14(2):106-11. PubMed ID: 8527391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
    Chu S; Li L; Singh H; Bhatia R
    Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation.
    McCallum L; Price S; Planque N; Perbal B; Pierce A; Whetton AD; Irvine AE
    Blood; 2006 Sep; 108(5):1716-23. PubMed ID: 16670264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.